TracyLLovellMD

Research History

• Phase III Cliinical Trial Sub-InvestigatorA Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients with Rheumatoid Arthritis.” Protocol MK-0663-107. Sponsored by Merck. October 2010 – June 2012.2010 - 2012
• Phase III Clinical Trial Sub-InvestigatorA Multicenter, Randomized, Long Term Study of the Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip.” Protocol A4091016. Sponsored by Pfizer2009 - 2011
• Phase III Clinical Trial Sub-InvestigatorAn Open-Label, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Tocilizumab (TCZ) Monotherapy or TCZ in Combination with Non-Biologic Disease Modifying Antirheumatic Drugs (DMARDs) in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biolo2009 - 2011
• Phase III Clinical Trial Sub-InvestigatorA Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Analgesic Efficacy, and Safety of Tanezumab in Patients with Osteoarthritis of the Hip. Sponsored by Pfizer2009 - 2010
• Phase IV Clinical Trial Sub-InvestigatorImpact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®.” Sponsored by Novartis Pharmaceuticals2008 - 2010
• Research FellowPathophysiology of antiphospholipid antibodies Principal Investigator: Robert R.A. Roubey, MD at University of North Carolina, Chapel Hill. Research has included creating a database of 397 patient blood samples and conducting ELISA assays to determine the role of antiprothrombin antibodies2003 - 2006
• Phase III Clinical Trial Sub-InvestigatorA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy.” Protocol: H9B-MC-BCDM, Sponsored by Eli Lilly.
• Phase III Clinical Trial Sub-InvestigatorA Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy.” Protocol: H9B-MC-BCDO, Sponsored by Eli Lilly.
• Phase III Clinical Trial Sub-InvestigatorA Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA).” Protocol: H9B-MC-BCDP. Sponsored by Eli Lilly
• Phase III Clinical Trial Sub-Investigator“A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one of more TNF-alpha Inhibitors.(Flex V).” Protocol: H9B-MC-BCDV
• Non Drug Intervention "F" Study Sub-InvestigatorA Multicenter Study of the Prevalence of Axial Spondyloarthritis (SpA) in the United States Among Subjects with Chronic Back Pain and Other SpA-Related Features.” Protocol: F12-117, Sponsored by Abbott.(Flex V).”